Registration is key

All this talk of takeover is fanciful. What company is going to take us over without regulatory approval for our flavocide or Qcide . Any real interest will only come with the registration of a recognised new class of chemistry. Last year's Annual Report stated that the expected date of the registration of our new novel mode of action is 2024. The recent appointment of Regulatory Affairs (Sarah Driessens) looks very good, and we are well on track with efficacy and field tests etc, but its still 2024 at the earliest. We are trying to replicate the last novel Mode of Action (Nihon's Diamedes) which took 10 years from its start to get to market (late 90's to 2008). So when we get closer to 2024 is when you can start posting multiples of market cap. Of course we can expect the share price to gradually move up when milestones are met, and commercial agreements are secured, and data is presented to the regulators.
Not sure what i dislike more, the new pumpers or the resident bears. By the way where is Masters? Hope he hung on